All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During The 6th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2021), the Lymphoma Hub was pleased to speak with Anna Sureda, Catalan Institute of Oncology, Barcelona, Spain. We asked, What role is there for allogeneic stem cell transplant in the treatment of Hodgkin lymphoma?
What role is there for allogeneic SCT in the treatment of Hodgkin lymphoma?
Sureda begins by outlining some important considerations for allogeneic hematopoietic stem cell transplant such as the use of haploidentical donors. She highlights that the introduction of new drugs like brentuximab have had an impact on reducing the number of allogenic transplants occurring. Finally, she discusses how a better knowledge of how to combine checkpoint inhibitors with allogenic stem cell transplants has led to improvements in the long term outcome of patients.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox